Clinical trial

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

NCT03712787

Study summary

ClinicalTrials.gov

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Tilavonemab Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2019-03-22

PhasePHASE2

Conditions

Alzheimer's Diseaseverified · MONDO: Alzheimer disease

Interventions

TilavonemabDRUG

Sponsors & collaborators

AbbVielead sponsor

Mapped research locations

HoustonTexas, United States2 BostonMassachusetts, United States2 BarcelonaSpain2 MilanItaly2 DallasTexas, United States1 AtlantaGeorgia, United States1 TorontoOntario, Canada1 NashvilleTennessee, United States1 San FranciscoCalifornia, United States1 MadridSpain1 TampaFlorida, United States1 PortlandOregon, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03712787 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.